IL-21 Half-Life Extension & Targeted Delivery Engineering Services
Creative Biolabs offers expert protein engineering and manufacturing to overcome native IL-21 limitations. We provide customized molecular design, creating proprietary IL-21 muteins with controlled potency and extended half-life via Fc or HSA fusion. We specialize in targeted delivery by producing immunocytokines that guide IL-21 activity to specific molecular targets, such as PD-1, ensuring localized immune activation. Backed by QbD-compliant biomanufacturing and in vitro validation, clients receive high-purity bulk protein and de-risked lead candidates with superior safety and efficacy for their immunotherapy programs.
Introduction What We Can Offer Types of Our Services Why Creative Biolabs Customer Reviews FAQs Related Services Contact Us
Engineering IL-21 to Overcome Therapeutic Limitations
Interleukin-21 (IL-21) is a critical type I cytokine recognized as a potent immune agonist that enhances the proliferation and effector function of CD8+ T cells and NK cells. While native IL-21 has demonstrated promising anti-tumor activities, its therapeutic application is severely limited by a short serum half-life, requiring high and frequent dosing. Furthermore, preclinical data show that while IL-21 activates T cells, it also simultaneously induces the expression of inhibitory checkpoints (PD-1, Tim-3, Lag-3), creating a self-limiting therapeutic feedback loop.
Explore our solutions and schedule your complimentary consultation now.
Fig.1 IL21R was differentially expressed among tumor-infiltrating immune cells. 1
What We Can Offer
Customized Mutein Library Design
We provide tailored IL-21 mutein generation, focusing on engineering variants with precisely attenuated potency to maximize the therapeutic window and minimize off-target systemic toxicity. This ensures localized activation at the tumor site.
Rational Targeting Strategy Development
Full support in selecting and designing the optimal targeting moiety (e.g., anti-PD-1, anti-CD20, or novel TME markers) to create highly specific and functionally synergistic immunocytokines.
End-to-End PK/PD Optimization
Integrated in silico modeling and rigorous in vitro validation services to ensure your engineered IL-21 construct achieves the desired serum half-life, systemic safety, and robust local biological activity.
QbD-Driven Process Development
Efficient upstream and downstream process development leveraging quality-by-design (QbD) principles to ensure product consistency and robust manufacturing protocols from the outset.
Types of IL-21 Half-Life Extension & Targeted Delivery Engineering Services at Creative Biolabs
Anti-PD-1/IL-21 Fusion Protein Development Service
This service is centered on the bifunctional immunocytokine strategy. We fuse an IL-21 mutein to an anti-PD-1 antibody (or fragment) to create a single molecule that provides both checkpoint blockade and localized IL-21 activation. This is ideal for overcoming T cell exhaustion in PD-1-high TMEs and has been shown to deliver superior results to simple combination therapy.
Learn More →
Anti-CD20/IL-21 Immunocytokine Development Service
Tailored for hematological malignancies or solid tumors with CD20 expression (e.g., in B cells or TME-associated structures). This service targets the IL-21 payload to CD20-expressing cells, capitalizing on IL-21's role in B cell regulation while ensuring anti-tumor immunity in the surrounding microenvironment.
Learn More →
Why Choose Us?
|
Core Advantages
|
Unique Features
|
|
Targeted IL-21 Mutein Design
|
We don't just extend the half-life; we incorporate rationally designed IL-21 muteins to precisely control cytokine potency, ensuring that high T cell activation occurs primarily at the tumor site where the targeting moiety concentrates.
|
|
Dual-Action Immunocytokine Expertise
|
Our Anti-PD-1/IL-21 fusion technology allows for a two-in-one therapeutic that simultaneously blocks an immune checkpoint and delivers an activating signal, offering superior efficacy over simple combinations of two separate agents.
|
|
Optimized Pharmacokinetics
|
Utilizing proven Fc and HSA-binding domain fusion technologies, we guarantee superior serum half-life, which is essential for achieving sustained anti-tumor immunity in vivo.
|
To fully understand the Creative Biolabs advantage, we invite you to get a quote today.
Customer Reviews
-
Reduced Systemic Toxicity
Using Creative Biolabs' IL-21 mutein design in our research has significantly improved the therapeutic window for our IL-21-based combinatorial regimen by eliminating toxicity concerns seen with wild-type cytokine. Their functional validation data were crucial for lead selection. – J**e B**.
-
Functional Combination Efficacy
The Anti-PD-1/IL-21 immunocytokine is a powerful tool. It not only blocks the PD-1 pathway but also provides a localized IL-21 boost precisely where it's needed, circumventing the counter-regulatory Tim-3 upregulation that derailed our previous dual-agent approach. – Ali** K**
FAQs
Q:
Will the IL-21 mutein designs compromise the therapeutic efficacy of the cytokine?
A:
Not at all. Our mutein designs are rationally attenuated to reduce systemic activity and prevent off-target toxicity. When these muteins are delivered locally via the targeting antibody (e.g., to the PD-1+ T cell surface), the local concentration is high enough to drive robust STAT3 signaling and effector function, as demonstrated by preclinical studies.
Q:
How does the targeted IL-21 fusion compare to just combining a free anti-PD-1 antibody and free IL-21?
A:
Preclinical data shows that combining free agents often induces significant systemic toxicity and, critically, can trigger counter-regulatory mechanisms (Tim-3, Lag-3) that limit efficacy. Our single-molecule fusion solves both issues: it reduces systemic toxicity and ensures the activating IL-21 signal is delivered only after the inhibitory PD-1 signal is blocked, creating a more synergistic and localized effect.
Related Services
TCR/CAR Expression Analysis
To ensure the quality and efficacy of engineered cell therapies, this service provides a comprehensive analysis of T cell receptor (TCR) and chimeric antigen receptor (CAR) expression.
Learn More →
Immunogenicity Prediction
The generation of engineered fusion proteins significantly increases the risk of anti-drug antibody (ADA) formation, which can compromise clinical safety and efficacy.
Learn More →
How to Contact Us
Creative Biolabs' IL-21 half-life extension & targeted delivery engineering services are your premier solution for moving beyond traditional cytokine therapy. The platform furnishes rationally designed IL-21 muteins and multi-functional immunocytokines, substantiated by robust preclinical evidence, to achieve superior pharmacokinetics (PK), mitigated toxicity, and enhanced T cell function for immunotherapy programs. Contact our team for more information and to discuss your project.
Reference
-
Wu, Shaoxian et al. "The Half-Life-Extended IL21 can Be Combined With Multiple Checkpoint Inhibitors for Tumor Immunotherapy." Frontiers in cell and developmental biology vol. 9 779865. 15 Nov. 2021. Distributed under an Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fcell.2021.779865
For Research Use Only | Not For Clinical Use
